Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Concomitant overexpression of EGFR and CXCR4 is associated with worse prognosis in a new molecular subtype of non-small cell lung cancer.

Al Zobair AA, Al Obeidy BF, Yang L, Yang C, Hui Y, Yu H, Zheng F, Yang G, Xie C, Zhou F, Zhou Y.

Oncol Rep. 2013 Apr;29(4):1524-32. doi: 10.3892/or.2013.2254. Epub 2013 Jan 29.

PMID:
23443279
2.
3.

Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients.

Ludovini V, Flacco A, Bianconi F, Ragusa M, Vannucci J, Bellezza G, Chiari R, Minotti V, Pistola L, Tofanetti FR, Siggillino A, Baldelli E, Sidoni A, Daddi N, Puma F, Varella-Garcia M, Crinò L.

Cancer Chemother Pharmacol. 2013 Mar;71(3):671-80. doi: 10.1007/s00280-012-2056-y. Epub 2013 Jan 12.

4.
5.

High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients.

Ludovini V, Bellezza G, Pistola L, Bianconi F, Di Carlo L, Sidoni A, Semeraro A, Del Sordo R, Tofanetti FR, Mameli MG, Daddi G, Cavaliere A, Tonato M, Crinò L.

Ann Oncol. 2009 May;20(5):842-9. doi: 10.1093/annonc/mdn727. Epub 2009 Jan 19.

6.

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M.

J Natl Cancer Inst. 2005 May 4;97(9):643-55.

7.

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS.

J Clin Oncol. 2011 Jul 20;29(21):2866-74. doi: 10.1200/JCO.2010.33.4235. Epub 2011 Jun 13.

9.

Cyclooxygenase-2 protein levels are independent of epidermal growth factor receptor expression or activation in operable non-small cell lung cancer.

Richardson CM, Richardson D, Swinson DE, Swain WA, Cox G, O'Byrne KJ.

Lung Cancer. 2005 Apr;48(1):47-57.

PMID:
15777970
10.

Depression, survival, and epidermal growth factor receptor genotypes in patients with metastatic non-small cell lung cancer.

Pirl WF, Traeger L, Greer JA, Jackson V, Lennes IT, Gallagher E, Sequist L, Temel JS.

Palliat Support Care. 2013 Jun;11(3):223-9. doi: 10.1017/S1478951512001071. Epub 2013 Feb 11.

PMID:
23399428
11.

Clinical significance of aberrant methylation of prostaglandin E receptor 2 (PTGER2) in nonsmall cell lung cancer: association with prognosis, PTGER2 expression, and epidermal growth factor receptor mutation.

Tian L, Suzuki M, Nakajima T, Kubo R, Sekine Y, Shibuya K, Hiroshima K, Nakatani Y, Fujisawa T, Yoshino I; Thoracic Surgery Group.

Cancer. 2008 Sep 15;113(6):1396-403. doi: 10.1002/cncr.23694.

12.

COX-2/EGFR expression and survival among women with adenocarcinoma of the lung.

Van Dyke AL, Cote ML, Prysak GM, Claeys GB, Wenzlaff AS, Murphy VC, Lonardo F, Schwartz AG.

Carcinogenesis. 2008 Sep;29(9):1781-7. doi: 10.1093/carcin/bgn107. Epub 2008 May 2.

13.

Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.

Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, Wang X, Duan CJ, Wu NM, Guo ZQ, Liu YX, Liu HN, Wang YY, Wang J.

J Clin Oncol. 2009 Jun 1;27(16):2653-9. doi: 10.1200/JCO.2008.17.3930. Epub 2009 May 4.

14.

Prognostic significance of MCM7 expression in the bronchial brushings of patients with non-small cell lung cancer (NSCLC).

Liu YZ, Jiang YY, Hao JJ, Lu SS, Zhang TT, Shang L, Cao J, Song X, Wang BS, Cai Y, Zhan QM, Wang MR.

Lung Cancer. 2012 Jul;77(1):176-82. doi: 10.1016/j.lungcan.2012.03.001. Epub 2012 Mar 26.

PMID:
22456526
15.

Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.

Zhang L, Yuan X, Chen Y, Du XJ, Yu S, Yang M.

Gene. 2013 Mar 15;517(1):60-4. doi: 10.1016/j.gene.2012.12.087. Epub 2013 Jan 9.

PMID:
23313300
16.

Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer.

Iwakiri S, Mino N, Takahashi T, Sonobe M, Nagai S, Okubo K, Wada H, Date H, Miyahara R.

Cancer. 2009 Jun 1;115(11):2580-93. doi: 10.1002/cncr.24281.

17.

A meta-analysis for CXCR4 as a prognostic marker and potential drug target in non-small cell lung cancer.

Zhang C, Li J, Han Y, Jiang J.

Drug Des Devel Ther. 2015 Jun 24;9:3267-78. doi: 10.2147/DDDT.S81564. eCollection 2015. Review.

18.

Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.

Haura EB, Zheng Z, Song L, Cantor A, Bepler G.

Clin Cancer Res. 2005 Dec 1;11(23):8288-94.

19.

Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer.

Kim SJ, Rabbani ZN, Dong F, Vollmer RT, Schreiber EG, Dewhirst MW, Vujaskovic Z, Kelley MJ.

Med Oncol. 2010 Mar;27(1):91-7. doi: 10.1007/s12032-009-9178-z. Epub 2009 Feb 24.

20.

Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.

Zucali PA, Ruiz MG, Giovannetti E, Destro A, Varella-Garcia M, Floor K, Ceresoli GL, Rodriguez JA, Garassino I, Comoglio P, Roncalli M, Santoro A, Giaccone G.

Ann Oncol. 2008 Sep;19(9):1605-12. doi: 10.1093/annonc/mdn240. Epub 2008 May 7.

Items per page

Supplemental Content

Write to the Help Desk